Hepatic Artery Infusion Chemotherapy for Hepatocellular Carcinoma: Clinical Advancements.

IF 2.8 4区医学 Q2 ONCOLOGY

Current oncology Pub Date : 2025-05-28 DOI:10.3390/curroncol32060313

Wei Xu, Qing Li, Bin Liang

引用次数: 0

Abstract

Intermediate- and advanced-stage hepatocellular carcinoma (HCC) continues to present significant therapeutic challenges. Hepatic artery infusion chemotherapy (HAIC), a well-established locoregional treatment for unresectable HCC, has recently demonstrated promising clinical outcomes both as monotherapy and in combination with systemic therapies. This comprehensive review examines recent clinical advances in HAIC for HCC, with particular emphasis on evolving treatment regimens and their therapeutic efficacy.

查看原文本刊更多论文

肝动脉灌注化疗治疗肝癌的临床进展。

中晚期肝细胞癌（HCC）继续呈现出显著的治疗挑战。肝动脉输注化疗（HAIC）是一种成熟的局部治疗不可切除HCC的方法，最近显示出有希望的临床结果，无论是单一治疗还是与全身治疗联合使用。本文综述了肝癌HAIC治疗的最新临床进展，特别强调了不断发展的治疗方案及其疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current oncology ONCOLOGY-

CiteScore

3.30

自引率

7.70%

发文量

664

审稿时长

1 months

期刊介绍： Current Oncology is a peer-reviewed, Canadian-based and internationally respected journal. Current Oncology represents a multidisciplinary medium encompassing health care workers in the field of cancer therapy in Canada to report upon and to review progress in the management of this disease. We encourage submissions from all fields of cancer medicine, including radiation oncology, surgical oncology, medical oncology, pediatric oncology, pathology, and cancer rehabilitation and survivorship. Articles published in the journal typically contain information that is relevant directly to clinical oncology practice, and have clear potential for application to the current or future practice of cancer medicine.